Because pharmacological and genetic ablation of FASN overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal [52], it might be worthwhile to evaluate whether the CCN1 Æ FASN angiogenesis/lipogenesis axis is responsible for the resistance to antiangiogenic therapies [53, 54]. The gene discussed is FASN; the disease is neoplasm.